MAUNA KEA TECHNOLOGIES (ALMKT) AI Stock Analysis

• Market Cap: €12.33M
• Dividend Yield: N/A
• Average Volume (3M): 830.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: -0.80%
• EPS Growth: 24.14%
• Country: FR
• Employees: 65
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.07
• Shares Outstanding: 174,945,140
• 10 Day Avg. Volume: 1,028,958
• 30 Day Avg. Volume: 830,169
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.44
• Price to Sales (P/S): 1.41
• P/FCF Ratio: -1.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: €0.00 ▼(-100.00% Downside)

Mauna Kea Technologies' overall stock score is primarily impacted by its poor financial performance and bearish technical indicators. The company's negative equity and persistent losses are significant concerns, while the technical analysis suggests continued downward pressure on the stock price. The negative P/E ratio further highlights valuation challenges.

Positive Factors

Innovative Product Offering

Mauna Kea's focus on innovative imaging systems like Cellvizio positions it well in the medical technology sector, potentially driving long-term growth through enhanced diagnostic capabilities.

Recurring Revenue Streams

The sale of consumables for each procedure provides a stable and recurring revenue stream, supporting long-term financial stability and growth.

Strategic Partnerships

Strategic partnerships enhance market access and distribution, strengthening Mauna Kea's competitive position and supporting sustainable growth.

Negative Factors

Declining Revenue

Significant revenue decline indicates challenges in market demand or competitive pressures, potentially impacting long-term financial health.

High Financial Leverage

High leverage and negative equity pose financial risks, limiting flexibility and potentially affecting the company's ability to sustain operations.

Negative Cash Flows

Persistent negative cash flows indicate operational inefficiencies and financial strain, threatening long-term viability without significant restructuring.

MAUNA KEA TECHNOLOGIES Business Overview & Revenue Model

Company Description

MAUNA KEA TECHNOLOGIES (ALMKT) is a pioneering medical technology company specializing in the development and commercialization of innovative imaging systems for the visualization of biological tissues. The company primarily operates in the healthcare sector, focusing on endomicroscopy solutions that enhance the capabilities of medical professionals in diagnosing and treating diseases, particularly in the fields of gastroenterology, pulmonology, and oncology. MAUNA KEA's flagship product is the Cellvizio system, which allows for real-time microscopic imaging at the cellular level, thereby improving patient outcomes through more accurate and timely interventions.

How the Company Makes Money

MAUNA KEA TECHNOLOGIES generates revenue through the sale of its proprietary imaging systems, including the Cellvizio platform, as well as disposable accessories required for its operation. The company earns money from direct sales to healthcare institutions, such as hospitals and outpatient clinics, as well as through leasing arrangements for its equipment. In addition to product sales, MAUNA KEA benefits from recurring revenue streams through the sale of consumables that are needed for each procedure performed using their technology. The company has also established strategic partnerships with key players in the medical device and healthcare sectors, which facilitate market access and enhance distribution channels, contributing significantly to its earnings.

MAUNA KEA TECHNOLOGIES Financial Statement Overview

Summary

Mauna Kea Technologies is facing severe financial difficulties with declining revenues, persistent losses, and high leverage. The negative equity position and substantial net losses overshadow the operational efficiency indicated by the gross profit margin.

Income Statement

Mauna Kea Technologies faced significant challenges with declining revenue and profitability. The revenue dropped by 30.6% from 2023 to 2024, and the company experienced negative net income, leading to a net profit margin of -135.9% in 2024. The gross profit margin was relatively strong at 84.1% but was insufficient to prevent substantial operating losses.

Balance Sheet

The balance sheet reveals a troubling debt-to-equity ratio due to negative equity, indicating high financial risk and leverage. With total liabilities exceeding total assets, the company is in a negative equity position, which may pose significant challenges in sustaining operations without restructuring its finances.

Cash Flow

Cash flow statements show negative operating and free cash flows, with a minor improvement in free cash flow compared to the previous year. However, the company remains in a precarious cash position, exacerbated by significant negative operating cash flows relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.18M	7.66M	11.03M	7.48M	7.70M	6.53M
Gross Profit	7.07M	6.44M	8.93M	3.91M	5.71M	3.63M
EBITDA	-4.45M	-7.97M	-1.46M	-9.93M	-11.23M	-11.43M
Net Income	-10.39M	-10.40M	-3.73M	-11.18M	-13.45M	-12.79M
Balance Sheet
Total Assets	12.66M	16.25M	22.94M	19.79M	24.75M	20.61M
Cash, Cash Equivalents and Short-Term Investments	663.00K	1.92M	7.91M	3.15M	11.89M	8.66M
Total Debt	32.87M	31.93M	29.77M	29.20M	28.70M	26.96M
Total Liabilities	42.08M	40.63M	40.21M	39.72M	35.08M	32.69M
Stockholders Equity	-29.42M	-24.39M	-17.28M	-19.92M	-10.33M	-12.08M
Cash Flow
Free Cash Flow	-5.00M	-6.54M	-1.14M	-8.97M	-11.37M	-9.07M
Operating Cash Flow	-4.80M	-6.32M	-753.00K	-8.83M	-10.27M	-7.99M
Investing Cash Flow	10.00K	-149.00K	-354.00K	-57.00K	-1.14M	-999.00K
Financing Cash Flow	1.68M	483.00K	5.96M	109.00K	14.65M	7.68M

MAUNA KEA TECHNOLOGIES Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMKT, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.27 is Neutral, neither overbought nor oversold. The STOCH value of 13.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMKT.

MAUNA KEA TECHNOLOGIES Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALMDT	48 Neutral	€116.12M	-2.71	―	―	6.75%	15.48%
ALTHE	45 Neutral	€30.00M	-4.98	-2351.12%	―	-4.70%	-64.31%
ALMKT	39 Underperform	€12.33M	-0.46	―	―	-0.80%	24.14%